Skip to main content

Siegfried Holding AG (SFZN.SW)

SIX Healthcare Drug Manufacturers - Specialty & GenericView data quality →
53.0Fair

ValueMarkers Composite Index

Top 42%#25,750 of 44,707
Overvalued

74% above intrinsic value ($57)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.95
Low Risk
Altman
4.01
Safe
DCF Value
$57
Overvalued
ROIC
9.2%
Adequate
P/E
20.7
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Siegfried Holding AG (SFZN.SW) — VMCI valuation read

Across 120 indicators, Siegfried Holding AG (SFZN.SW) lands at VMCI 53/100. The Healthcare sector median is 50, so the 3-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on SFZN.SW in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, SFZN.SW trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 0.9x leaves covenant headroom for SFZN.SW on the trailing balance sheet.

SFZN.SW rose 3.4% over the trailing 7 days, with a +5.2% read on a 30-day basis.

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

CEO: Marcel Imwinkelried3,886 employeesCHwww.siegfried.ch

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SFZN.SW’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.